Which has preferable earnings & valuation, ONC or GSK?

GSK has higher revenue and earnings than BeOne Medicines. GSK is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BeOne Medicines $5.34B 5.69 $286.93M $4.47 62.00 GSK $43.07B 2.40 $7.54B $3.85 13.29

Is ONC or GSK more profitable?

GSK has a net margin of 17.82% compared to BeOne Medicines' net margin of 8.94%. GSK's return on equity of 44.28% beat BeOne Medicines' return on equity. Company Net Margins Return on Equity Return on Assets BeOne Medicines 8.94% 12.06% 6.69% GSK 17.82% 44.28% 11.49%

Does the media prefer ONC or GSK?

In the previous week, BeOne Medicines had 7 more articles in the media than GSK. MarketBeat recorded 12 mentions for BeOne Medicines and 5 mentions for GSK. GSK's average media sentiment score of 1.10 beat BeOne Medicines' score of -0.46 indicating that GSK is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral GSK 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, ONC or SNY?

Sanofi has higher revenue and earnings than BeOne Medicines. Sanofi is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BeOne Medicines $5.34B 5.69 $286.93M $4.47 62.00 Sanofi $49.35B 2.03 $8.84B $3.58 11.54

Is ONC or SNY more profitable?

Sanofi has a net margin of 16.95% compared to BeOne Medicines' net margin of 8.94%. Sanofi's return on equity of 13.39% beat BeOne Medicines' return on equity. Company Net Margins Return on Equity Return on Assets BeOne Medicines 8.94% 12.06% 6.69% Sanofi 16.95% 13.39% 7.58%

Does the media refer more to ONC or SNY?

In the previous week, BeOne Medicines had 7 more articles in the media than Sanofi. MarketBeat recorded 12 mentions for BeOne Medicines and 5 mentions for Sanofi. Sanofi's average media sentiment score of 0.54 beat BeOne Medicines' score of -0.46 indicating that Sanofi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Sanofi 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ARGX or ONC more profitable?

argenex has a net margin of 31.31% compared to BeOne Medicines' net margin of 8.94%. argenex's return on equity of 44.37% beat BeOne Medicines' return on equity. Company Net Margins Return on Equity Return on Assets argenex 31.31% 44.37% 37.55% BeOne Medicines 8.94% 12.06% 6.69%

Does the media favor ARGX or ONC?

In the previous week, BeOne Medicines had 7 more articles in the media than argenex. MarketBeat recorded 12 mentions for BeOne Medicines and 5 mentions for argenex. argenex's average media sentiment score of 0.00 beat BeOne Medicines' score of -0.46 indicating that argenex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BeOne Medicines 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate TAK or ONC?

BeOne Medicines has a consensus price target of $390.00, suggesting a potential upside of 40.73%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts clearly believe BeOne Medicines is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 BeOne Medicines 1 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 2.93

Does the media prefer TAK or ONC?

In the previous week, BeOne Medicines had 10 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 12 mentions for BeOne Medicines and 2 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.17 beat BeOne Medicines' score of -0.46 indicating that Takeda Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BeOne Medicines 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer TEVA or ONC?

In the previous week, Teva Pharmaceutical Industries had 17 more articles in the media than BeOne Medicines. MarketBeat recorded 29 mentions for Teva Pharmaceutical Industries and 12 mentions for BeOne Medicines. Teva Pharmaceutical Industries' average media sentiment score of 1.07 beat BeOne Medicines' score of -0.46 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 17 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeOne Medicines 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

BeOne Medicines (ONC) Competitors

$277.12 +0.99 (+0.36%)

Closing price 04:00 PM Eastern

Extended Trading

$273.85 -3.27 (-1.18%)

As of 05:23 PM Eastern

Compare

ONC vs. GSK, SNY, ARGX, TAK, and TEVA

Should you buy BeOne Medicines stock or one of its competitors? MarketBeat compares BeOne Medicines with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BeOne Medicines include GSK (GSK), Sanofi (SNY), argenex (ARGX), Takeda Pharmaceutical (TAK), and Teva Pharmaceutical Industries (TEVA). These companies are all part of the "pharmaceutical products" industry.

How does BeOne Medicines compare to GSK?

BeOne Medicines (NASDAQ:ONC) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

GSK has higher revenue and earnings than BeOne Medicines. GSK is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	5.69	$286.93M	$4.47	62.00
GSK	$43.07B	2.40	$7.54B	$3.85	13.29

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by insiders. Comparatively, 10.0% of GSK shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

GSK has a net margin of 17.82% compared to BeOne Medicines' net margin of 8.94%. GSK's return on equity of 44.28% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
GSK	17.82%	44.28%	11.49%

BeOne Medicines presently has a consensus price target of $390.00, indicating a potential upside of 40.73%. GSK has a consensus price target of $53.00, indicating a potential upside of 3.62%. Given BeOne Medicines' stronger consensus rating and higher possible upside, equities analysts plainly believe BeOne Medicines is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
GSK	3 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.00

BeOne Medicines has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, GSK has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market.

In the previous week, BeOne Medicines had 7 more articles in the media than GSK. MarketBeat recorded 12 mentions for BeOne Medicines and 5 mentions for GSK. GSK's average media sentiment score of 1.10 beat BeOne Medicines' score of -0.46 indicating that GSK is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
GSK	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BeOne Medicines beats GSK on 10 of the 17 factors compared between the two stocks.

How does BeOne Medicines compare to Sanofi?

BeOne Medicines (NASDAQ:ONC) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

Sanofi has higher revenue and earnings than BeOne Medicines. Sanofi is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	5.69	$286.93M	$4.47	62.00
Sanofi	$49.35B	2.03	$8.84B	$3.58	11.54

BeOne Medicines has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market.

Sanofi has a net margin of 16.95% compared to BeOne Medicines' net margin of 8.94%. Sanofi's return on equity of 13.39% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Sanofi	16.95%	13.39%	7.58%

BeOne Medicines presently has a consensus price target of $390.00, suggesting a potential upside of 40.73%. Sanofi has a consensus price target of $51.00, suggesting a potential upside of 23.40%. Given BeOne Medicines' stronger consensus rating and higher possible upside, equities analysts plainly believe BeOne Medicines is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47

In the previous week, BeOne Medicines had 7 more articles in the media than Sanofi. MarketBeat recorded 12 mentions for BeOne Medicines and 5 mentions for Sanofi. Sanofi's average media sentiment score of 0.54 beat BeOne Medicines' score of -0.46 indicating that Sanofi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sanofi	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by company insiders. Comparatively, 1.0% of Sanofi shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

BeOne Medicines beats Sanofi on 10 of the 16 factors compared between the two stocks.

How does BeOne Medicines compare to argenex?

argenex (NASDAQ:ARGX) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

argenex has higher earnings, but lower revenue than BeOne Medicines. argenex is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	12.48	$1.29B	$22.46	37.96
BeOne Medicines	$5.34B	5.69	$286.93M	$4.47	62.00

argenex presently has a consensus price target of $1,023.39, suggesting a potential upside of 20.05%. BeOne Medicines has a consensus price target of $390.00, suggesting a potential upside of 40.73%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts plainly believe BeOne Medicines is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

60.3% of argenex shares are held by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are held by institutional investors. 2.4% of argenex shares are held by insiders. Comparatively, 6.2% of BeOne Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

argenex has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

In the previous week, BeOne Medicines had 7 more articles in the media than argenex. MarketBeat recorded 12 mentions for BeOne Medicines and 5 mentions for argenex. argenex's average media sentiment score of 0.00 beat BeOne Medicines' score of -0.46 indicating that argenex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BeOne Medicines	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

argenex has a net margin of 31.31% compared to BeOne Medicines' net margin of 8.94%. argenex's return on equity of 44.37% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	31.31%	44.37%	37.55%
BeOne Medicines	8.94%	12.06%	6.69%

Summary

argenex beats BeOne Medicines on 9 of the 16 factors compared between the two stocks.

How does BeOne Medicines compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

Takeda Pharmaceutical has a beta of -0.07, suggesting that its share price is 107% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

BeOne Medicines has a net margin of 8.94% compared to Takeda Pharmaceutical's net margin of 4.31%. BeOne Medicines' return on equity of 12.06% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.31%	11.20%	5.48%
BeOne Medicines	8.94%	12.06%	6.69%

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

BeOne Medicines has lower revenue, but higher earnings than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	1.77	-$1.01B	$0.39	40.35
BeOne Medicines	$5.34B	5.69	$286.93M	$4.47	62.00

In the previous week, BeOne Medicines had 10 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 12 mentions for BeOne Medicines and 2 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.17 beat BeOne Medicines' score of -0.46 indicating that Takeda Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BeOne Medicines	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

BeOne Medicines has a consensus price target of $390.00, suggesting a potential upside of 40.73%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts clearly believe BeOne Medicines is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

Summary

BeOne Medicines beats Takeda Pharmaceutical on 15 of the 17 factors compared between the two stocks.

How does BeOne Medicines compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

In the previous week, Teva Pharmaceutical Industries had 17 more articles in the media than BeOne Medicines. MarketBeat recorded 29 mentions for Teva Pharmaceutical Industries and 12 mentions for BeOne Medicines. Teva Pharmaceutical Industries' average media sentiment score of 1.07 beat BeOne Medicines' score of -0.46 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	17 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BeOne Medicines	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Teva Pharmaceutical Industries has higher revenue and earnings than BeOne Medicines. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.28	$1.41B	$1.33	25.72
BeOne Medicines	$5.34B	5.69	$286.93M	$4.47	62.00

Teva Pharmaceutical Industries has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market.

Teva Pharmaceutical Industries has a net margin of 9.01% compared to BeOne Medicines' net margin of 8.94%. Teva Pharmaceutical Industries' return on equity of 43.53% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%
BeOne Medicines	8.94%	12.06%	6.69%

Teva Pharmaceutical Industries presently has a consensus target price of $41.78, indicating a potential upside of 22.14%. BeOne Medicines has a consensus target price of $390.00, indicating a potential upside of 40.73%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts plainly believe BeOne Medicines is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Teva Pharmaceutical Industries beats BeOne Medicines on 9 of the 17 factors compared between the two stocks.

Get BeOne Medicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ONC vs. The Competition

Export

Metric	BeOne Medicines	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$30.30B	$2.99B	$6.74B	$12.32B
Dividend Yield	N/A	1.78%	2.68%	5.88%
P/E Ratio	62.00	18.65	25.39	23.96
Price / Sales	5.69	341.96	530.17	107.90
Price / Cash	70.65	56.64	45.29	53.76
Price / Book	6.97	4.14	10.76	6.41
Net Income	$286.93M	$64.45M	$3.56B	$337.14M
7 Day Performance	5.50%	1.34%	1.37%	-0.48%
1 Month Performance	-10.68%	0.95%	0.81%	0.49%
1 Year Performance	3.87%	24.33%	30.53%	28.16%

BeOne Medicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ONC BeOne Medicines	4.1189 of 5 stars	$277.12 +0.4%	$390.00 +40.7%	+7.2%	$30.30B	$5.34B	62.00	12,000
GSK GSK	3.3878 of 5 stars	$53.04 +0.3%	$53.00 -0.1%	+36.1%	$107.41B	$43.07B	13.78	66,841	Positive News Dividend Cut
SNY Sanofi	4.6533 of 5 stars	$44.25 +0.3%	$51.00 +15.3%	-13.7%	$107.28B	$49.35B	12.36	74,846	News Coverage
ARGX argenex	4.0588 of 5 stars	$893.52 -0.6%	$1,019.50 +14.1%	+57.8%	$55.57B	$4.25B	39.78	1,863	News Coverage Analyst Forecast
TAK Takeda Pharmaceutical	2.9868 of 5 stars	$15.92 +0.3%	N/A	+7.5%	$50.63B	$28.32B	40.81	47,455	News Coverage Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ONC) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BeOne Medicines (ONC) Competitors

ONC vs. GSK, SNY, ARGX, TAK, and TEVA

How does BeOne Medicines compare to GSK?

Summary

How does BeOne Medicines compare to Sanofi?

Summary

How does BeOne Medicines compare to argenex?

Summary

How does BeOne Medicines compare to Takeda Pharmaceutical?

Summary

How does BeOne Medicines compare to Teva Pharmaceutical Industries?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONC vs. The Competition

BeOne Medicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BeOne Medicines (ONC) Competitors

ONC vs. GSK, SNY, ARGX, TAK, and TEVA

How does BeOne Medicines compare to GSK?

Which has preferable earnings & valuation, ONC or GSK?

Do insiders & institutionals believe in ONC or GSK?

Is ONC or GSK more profitable?

Do analysts recommend ONC or GSK?

Which has more risk & volatility, ONC or GSK?

Does the media prefer ONC or GSK?

Summary

How does BeOne Medicines compare to Sanofi?

Which has better valuation and earnings, ONC or SNY?

Which has more risk & volatility, ONC or SNY?

Is ONC or SNY more profitable?

Do analysts recommend ONC or SNY?

Does the media refer more to ONC or SNY?

Do institutionals and insiders hold more shares of ONC or SNY?

Summary

How does BeOne Medicines compare to argenex?

Which has stronger valuation & earnings, ARGX or ONC?

Do analysts recommend ARGX or ONC?

Do institutionals and insiders have more ownership in ARGX or ONC?

Which has more risk and volatility, ARGX or ONC?

Does the media favor ARGX or ONC?

Is ARGX or ONC more profitable?

Summary

How does BeOne Medicines compare to Takeda Pharmaceutical?

Which has more risk & volatility, TAK or ONC?

Is TAK or ONC more profitable?

Do insiders and institutionals hold more shares of TAK or ONC?

Which has preferable valuation and earnings, TAK or ONC?

Does the media prefer TAK or ONC?

Do analysts rate TAK or ONC?

Summary

How does BeOne Medicines compare to Teva Pharmaceutical Industries?

Does the media prefer TEVA or ONC?

Which has higher valuation & earnings, TEVA or ONC?

Which has more risk and volatility, TEVA or ONC?

Is TEVA or ONC more profitable?

Do analysts recommend TEVA or ONC?

Do insiders and institutionals believe in TEVA or ONC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONC vs. The Competition

BeOne Medicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools